Role of *Aspergillus* Galactomannan Antigen Test for the Screening of Invasive Aspergillosis in Patients with Hematological Malignancies

Eman H. Salem[1*], Asmaa M. Elbrolosy[1], Samah M. Awad[2], Suzan A. Alhassanin[3], Amira I. Aldesoky[3], Suzy F. Gohar[3] and Shaimaa S. Solimani[4]

[1]*Department of Medical Microbiology and Immunology, Faculty of Medicine, Menofia University, Egypt.*
[2]*Department of Clinical Microbiology and Immunology, National Liver Institute, Menofia University, Egypt.*
[3]*Depatment of Clinical Oncology, Faculty of Medicine, Menofia University, Egypt.*
[4]*Depatment of Public Health and Community Medicine, Faculty of Medicine, Menofia University, Egypt.*

Authors' contributions

This work was carried out in collaboration between all authors. Author EHS designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors AME, SFG, SAA and SSS managed the analyses of the study. Authors SMA and AIA managed the literature searches. All authors read and approved the final manuscript.

Original Research Article

ABSTRACT

Background: Invasive aspergillosis (IA) is a leading cause of death among immunocompromised patients, particularly those with hematological malignances. The use of galactomannan (GM) antigen as a biological marker for screening of IA in high-risk patients is attractive and non-invasive tool that detect evidence of IA prior to the appearance of clinical manifestations.
Objectives: The aim of this study was to compare the diagnostic value of the conventional blood

_____

Corresponding author: E-mail: emansalem453@yahoo.com;

culture technique to the serological detection of GM antigen using ELISA for screening of IA in neutropenic patients with hematological malignancies.

Methods: Forty patients with haematological malignancies from those admitted to the Clinical Oncology Department of Menoufia University Hospitals (MUH) were enrolled and classified to have either proven (5/40; 12.5%), probable (10/40; 25%) or possible (25/40; 62.5%) invasive aspergillosis based on the clinical criteria provided by the European Organization for research and treatment of Cancer (EORTC) and Mycoses Study Group (MSG). Blood samples were collected from all participants and subjected to conventional blood culture for isolation and identification of *Aspergillus* spp. ELISA technique was applied for serological detection of GM antigen in the patients' serum samples.

Results: The sensitivity, specificity, PPV(positive predictive value) and NPV (negative predictive value of GM antigen ELISA testing were 100%, 74%, 36% and 100% respectively for both proven and probable cases. On applying the principle of test in series (the patient is positive if positive in both culture and the GM test), the results were improved to 100% sensitivity, 100% specificity, 100% PPV, 100% NPV and 100% accuracy. Galactomannan antigen testing proved excellent sensitivity (80%) compared to other clinical features and radiological criteria for diagnosis of probable aspergillosis and proved to be a good negative test.

Conclusion: With conjunction of clinical and radiological signs, *Aspergillus* GM test can assist physicians in the of diagnosis of IA in patients with hematological malignancies to allow initiation of effective antifungal therapy which is ultimately important in high-risk populations.

1. INTRODUCTION

Invasive fungal infections (IFI) are associated with high morbidity and mortality in immunocompromised patients with hematological malignances [1]. Several factors are incriminated in increasing frequency of IFI among those patients like dose-intensive regimens, mucosal damage (due to chemotherapy) and widespread use of broad-spectrum antibiotics [2].

Diagnosis of IFI in patients with hematologic malignances remains difficult and challenging since the clinical symptoms are often difficult to distinguish from symptoms of bacterial or viral infections. Moreover, conventional diagnostic methods are associated with short comings due to lack of sensitivity of conventional culture methods. Non-culture-based techniques, such as detection of DNA by PCR or measurements of fungal biomarkers in blood or respiratory samples, are important adjunctive tools [3,4].

Invasive aspergillosis (IA) is a potentially life-threatening infection, caused mainly by different *Aspergillus* spp. of which *A. fumigatus* is the most prevalent. In serious cases, *A. fumigatus* may spread from the lung to other organs, resulting in haematogenously disseminated fungal disease [5].

Galactomannan (GM) is a polysaccharide antigen that exists primarily in the cell walls of *Aspergillus* spp. GM may be released into the blood and other body fluids even in the early stages of *Aspergillus* invasion and the presence of this antigen can be sustained for 1 to 8 weeks. Therefore, detection of the GM antigen level via enzyme linked immunosorbent assay (ELISA) can be useful in making an early diagnosis of invasive aspergillosis [6].

Currently, serum GM detection is considered a microbiological diagnostic criterion for fungus infection in neutropenic patients, according to the guidelines of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) [7]. Detection of GM antigen in serum and recently in other body fluids provides easily performed assays for mycological supportive criteria that in conjunction with imaging scan findings can be used to support the diagnosis of probable IFI [8].

Because early diagnosis of IFI became necessary to avoid delaying in treatment initiation which is associated with an increased mortality [9], here came the aim of this research which tried to find out the validity of serological detection of *Aspergillus* GM antigen in relation to the conventional culture methods for the screening of invasive aspergillosis in neutropenic patients with hematological malignancies at Menoufia University Hospitals.

2. PATIENTS AND METHODS

This study was conducted from March to June 2019 at the Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University in collaboration with Clinical Oncology Department and Clinical Microbiology and Immunology Department of the National Liver Institute.

2.1 Study Population

This study included 40 patients (14 females and 26 males) with mean age of 52.32 ± 10.05 years, with hematological malignancies (lymphomas and leukemias) who were admitted to the Clinical Oncology Department with suspected IFI.

2.2 Collected Data

All patients were subjected to full history taking including name, age, sex, type of malignancy, type, dose and duration of chemotherapy (immunosuppressive), history of antibiotics and or antifungals received. General examination was also performed for body temperature recording, examination of oral cavity for ulcers or thrush, looking for nasal ulcers or sinusitis, chest, abdominal and CNS examination. All selected patients had no previous history of *Aspergillus* GM antigen testing.

Routine laboratory data including baseline complete blood picture (CBC), liver and kidney function, radiological findings as chest X-ray and CT scan were collected from patients' files, for detection of internal organ involvement. Blood samples for fungal and bacterial culture, swabs were taken from suspected sites of infection (when possible) for fungal analysis.

2.3 Specimen Collection

Blood samples were collected by withdrawing 10 ml of venous blood from each adult patient and 2–5 ml from infants and children under strict aseptic conditions. The sample was divided as follows; 0.5 ml in infants to 1.5 ml in adult; were inoculated into culture bottles in BACT/ALERT 3D system (BioMerieux) for five days. Upon appearance of any alarm indicative of possible growth in the blood culture bottle, subculture were made on Sabaroud's Dextrose media (BD Bioxon)at 37°C for 2-5 days for detection of *Aspergillus* spp. and other fungal infections in the patient's blood.

Identification of *Aspergillus* spp.: Microscopic examination of Gram stained film of *Aspergillus* spp. showed Gram positive septate hyphae with dichotomous branching. *A. fumigatus* produced a fluffy and granular colony and exhibited blue-green powdery appearance. *A. flavus* produced a yellow-green colony. *A. niger* began as a yellow colony that soon became black, dotted surface as conidia are produced. With age the colony became jet black [10].

Identification of *Candida* spp.: Up to species level was performed by culture onto Brilliance™ *Candida* Agar [Oxoid Chromogenic Candida Agar (OCCA) CODE: CM1002; England]; the inoculated plates were inspected for the growth of *Candida* spp. at 24, 48 and 72 hrs. The grown colonies were identified according to their expected reactions on the plate [11].

Identification of the isolated bacterial spp.: Also, subcultures were made on nutrient, blood, mannitol salt and MacConkey's agars and incubated aerobically at 37°C for 24-48 h for identification of possible mixed bacterial infection. The resultant colonies were subjected to further morphological and biochemical reactions to identify different bacterial species according to the standard microbiological methods [12].

2.4 Serological Detection of *Aspergillus* Galactomannan Antigen

Aspergillus GM antigen was detected in patient's serum via enzyme-linked immunosorbent assay (PLATELIA™ ASPERGILLUS Ag BIO-RAD USA) according to the manufacture's instructions; 2 ml of whole blood were allowed to clot and serum was separated, divided into aliquots and stored at 2°C to 8°C for up to 48 h or frozen at −80°C until testing for GM antigen. To calculate the mean cut-off control OD, the OD values for each cut-off control were added together and the result was divided by 2 and the index of each test sample was calculated by dividing the OD of the sample by the mean cut-off control OD, the results were interpreted as index (I): serum with index less than < 0.50 and index ≥ 0.50were respectively considered to be negative and positive for GM antigen in both male and female patients.

Different specimens of suspected clinical sites were also obtained from 10 patients (pus, oral swaps, vaginal swaps and sputum) and inoculated onto nutrient, blood, mannitol salt and

MacConkey's agars and incubated aerobically at 37°C for 24-48 h; for identification of bacterial infection. The resultant colonies were subjected to further morphological and biochemical reactions to identify different bacterial species according to the standard microbiological methods. Specimens were inoculated also onto Sabaroud's Dextrose agar at 37°C (BD Bioxon) for detection the presence or absence of fungal infection (*Candida* spp. and *Aspergillus* spp.) [12].

The culture results were identified, total period of patients' admission during their illness was identified, and also patient's fate and the average cost for admission per patient were calculated.

The study populations were categorized into three groups {as per the international consensus of the IFI cooperative group of the European Organization for research and treatment of Cancer (EORTC) and Mycoses Study Group (MSG)} [7]. Group I involved 5 patients with aspergillosis: confirmed by positive blood culture. Group II involved 10 patients with probable aspergillosis. Patients in this group were those who had a host factor like recent history of neutropenia and uncontrolled fever despite use of broad-spectrum antibiotics, a clinical feature such as the presence of 1 of the 3 signs on CT chest e.g. dense, well circumscribed lesions (s) with or without a halo sign, air-crescent sign or cavity, tracheobronchial ulceration, nodule, pseudo-membrane, plaque, or eschar seen on bronchoscope analysis, sino-nasal infection, Imaging showing sinusitis plus, acute localized pain or nasal ulcer with black eschar, CNS infection with focal lesions and/or meningeal enhancement on MRI or CT). This in addition to a mycological evidence in the form of positive microscopy or culture from samples such as sputum, bronchoalveolar lavage or sinus aspirate. *Aspergillus* GM antigen test was excluded as criterion of probable fungal infection. Group III involved 25 patients with host and clinical factors but without mycological evidence (possible cases).

2.5 Statistical Analysis

Data were analyzed by SPSS statistical package version 23 (SPSS Inc. Released 2015. IBM SPSS statistics for windows, version 23.0, Armnok, NY: IBM Corp.). ANOVA test was used for comparison of quantitative variables between more than two groups of normally distributed data. Chi-square test ($\chi2$) was used to study association between qualitative variables.

Whenever any of the expected cells were less than five, Fischer's Exact test was used. Two sided P- value of < 0.05 was considered statistically significant.

3. RESULTS

The mean age of the participants was 52.32±10.05 years. Twenty percent (8/40) of the patients had chronic lymphocytic leukemia (CLL), 10% (4/40) had acute myeloid leukemia (AML), 57.5% (23/40) had non-Hodgkin's lymphoma (NHL), 10% (4/40) had acute lymphocytic leukemia (ALL) and 2.5% (1/40) had relapsed Hodgkin's diseases (HD).

Bacterial blood culture was positive in15 patients only; representing 37.5% of all the included cases and the most commonly isolated bacterial species were *Klebsiella pneumoniae.* Fungaemia was present in 9 cases (22.5%); four cases were *Candida albicans* (10%) and 5 cases were Aspergillus 12.5%) (Table1).

The prevalence of invasive fungal infection (proven and probable) was 22.5% (9/40 patients), among them 5 patients only had positive culture for invasive Aspergillosis (12.5%) as shown in (Fig. 1). Among them, *Aspergillus* GM antigen was positive in 100% (5/5), 80% (8/10), and 4% (1/25) of patients with proven, probable and possible fungal infection respectively (Fig. 1).

In relation to the standard blood culture results, the GM had 100% sensitivity, 74.0% specificity, 36.0% PPV, 100.0% NPV and 78.0% over all accuracy among the whole studied groups.

On applying the concept of test in parallel (the patient is positive if positive in the culture or the GM), no more diagnostic value were added to the results of GM validity (100% sensitivity, 74.0% specificity, 36.0% PPV, 100.0% NPV and 78.0% all over accuracy). While on applying the principle of test in series (the patient is positive if positive in both culture and the GM), the results were improved to 100% sensitivity, 100% specificity, 100% PPV, 100% NPV and 100% all over accuracy (Table 2).

Comparison between the studied patients' groups according to their clinical features showed no significant difference regarding their age, gender or initial diagnosis. Bacterial culture positivity was more among cases with possible fungal infection (Table 4).

The prognosis of patients with invasive aspergillosis was analyzed in Table 5 where, the mortality rate among patients with invasive aspergillosis diagnosed by GM antigen detection reached 50% while for patients with invasive aspergillosis diagnosed by blood culture detection, it was 80%.

Table 1. Demographic characteristic of studied patients

	No. (%)
Age (mean ±SD, range)	52.32 ± 10.05, 29-72
Gender	
Male	26 (65.0)
Female	14 (35.0)
Diagnosis	
CLL	8 (20.0)
AML	4 (10.0)
NHL	23 (57.5)
ALL	4 (10.0)
Relapsed HD	1 (2.5)
Bacterial culture	
Positive	15 (37.5)
Negative	25 (62.5)
Bacterial species	
Streptococcus	1 (2.5)
Klebsiella pneumoniae	10 (25.0)
E coli	3 (7.5)
Mixed	1 (2.5)
Fungal blood culture	
Positive	9 (22.5)
Negative	31 (77.5)
Fungal species	
Candida albicans	4 (10.0)
Aspergillus fumigatus	2 (5.0)
Aspergillus flavus	2 (5.0)
Aspergillus niger	1 (2.5)

4. DISCUSSION

Invasive aspergillosis (IA) represents a serious threat in patients with depressed immune system. Patients diagnosed with hematologic malignancies and chemotherapy-induced neutropenia or hematopoietic stem cell transplantations (HSCT) are at highest risk [13].

The current diagnostic limitations require improvement for detection of fungal pathogens by defining the optimal use of biomarkers and clinical samples. Being invasive, histopathological examination not done in most patients and proven cases are diagnosed based on positive blood culture for aspergillosis. Therefore, sensitive assays for accurate diagnosis of the fungal infection are needed [14,15].

In the current study 40 patients with different types of hematological malignances like lymphoma and leukemia were enrolled. Patients were classified to have either proven (5/40; 12.5%), probable (10/40; 25%) or possible (25/40; 62.5%) invasive fungal infection as per the European Organization for research and treatment of Cancer (EORTC) and Mycoses Study Group (MSG).

Among the studied population, the incidence of proven, probable and possible aspergillosis was 12.5%, 20% and 2.5% respectively. Zhang et al [15] reported that, among the studied population the incidence of proven aspergillosis was 0.8%, probable aspergillosis was 14.0% and possible aspergillosis was 7.4%. Dos Santosa et al. [16], reported that overall incidence of invasive aspergillosis (proven and probable) detected by *Aspergillus* GM screening test in hospital in Brazil was 12.2%, and, Penack et al. [17] who found the incidence of proven, probable and possible IA was 6%, 2.5% and 15.5%, respectively. The previously reported data provide additional support for the importance and seriousness of the IA infection in this group of immunosuppressed patients.

PLATELIA™ *Aspergillus* kit for detection of GM antigen has been used in diagnosis of invasive aspergillosis with the standard blood culture method; Considering true positives as the only results obtained for patients with proven and probable IA; the sensitivity, specificity, positive and negative predictive values of GM testing in parallel to the standard blood culture in diagnosing of proven *Aspergillus* infection were 100, 74, 36, 100 and 78 % respectively. And this was comparable to that found by Foy et al. [18] who found the sensitivity of both GM antigen test and blood culture were the same (100%), and Pfeiffer et al. [19] who found the sensitivity and specificity of GM testing in proven cases of invasive aspergillosis were 71% and 89% respectively. On the other hand, Penack et al. [17] reported that GM testing had excellent specificity (100%) and sensitivity was relatively low (40%) at onset of fever, but increased to 94.7% after 6 days of fever and in study

conducted by Ahmad, et al. [2] PPV and NPV were 79% and 83% respectively which is lower than our results this may be due to different study design as we directly compare between blood culture and GM ELISA test.

The sensitivity of galactomannan assay for IA has been variably reported among studies. This variability in the assay may be related in part to the hosts, their exposure to antifungal agents and cut-off value of a positive GM result. The excellent sensitivity and negative predictive value make this approach suitable for clinical decision making.

Among probable cases; the sensitivity, specificity, PPN and NPV were as follow 100%, 74%, 36% and 100% respectively, these values were close to that reported by Tănase et al., [20] who found the Sensitivity (85%), Specificity (91%), PPV (46%) and NPV (99%). On the other hand Pfeiffer et al. [19] reported the sensitivity and specificity of GM testing in diagnosis of probable cases of invasive aspergillosis were 61% and 93% respectively.

Eight out of ten patients diagnosed as probable fungal infection had positive galactomannan test, indicating excellent sensitivity of *Aspergillus* GM antigen test compared to other clinical features and radiological criteria for diagnosis of probable aspergillosis (80% versus100%), with its high NPV it is a good negative test.

However, both the test and the other features for probable fungal infection are troubled with its low

PPV. Making combination of the test with other features for diagnosing patients with probable infection considered and recommended by De Pauw et al. [7] and Tănase et al. [20].

Many false-positive test results were reported with the GM assay, and this because some number of β-lactam antibiotics, including Penicillium, piperacillin/tazobactam, amoxicillin/clavulanate, and ampicillin have yielded positive Platelia EIA results. False positive results were reported more frequently in children and it was suggested that GM in present in milk or protein-rich nutrients and this was the cause of false-positive results in children. This was supported by the high false positive rate (83%) reported in newborn babies by Mennink-Kersten et al. [8]. Other causes related to false positive results including: infection with organisms that share cross-reacting antigens with *Aspergillus*, reduced renal clearance, patients undergoing liver transplantation for autoimmune liver disease, patients undergoing cyclophosphamide treatment, patients undergoing lung transplantation for cystic fibrosis and chronic obstructive pulmonary disease [8].

Also, false- negative test results are reported with the GM assay, the main reason for it was exposure to antifungal agents but, other causes were also important including: inappropriate diagnostic criteria for IA, inadequate frequency of galactomannan testing, patients with non or minimally invasive manifestation of aspergillosis and low volume of sampling or long-term storage of samples [8].

Fig. 1. The percent's of invasive aspergillosis by both blood culture technique and GM antigen detection techniques in the studied group

Table 2. Validity of *Aspergillus* GM test in parallel to the standard blood culture for diagnosis of proven *Aspergillus* infection

	Sensitivity	Specificity	PPV	NPV	Accuracy
Aspergillus galactomannan antigen test	100%	74%	36%	100%	78%
Aspergillus Culture	100%	100%	100%	100%	100%

Table 3. Validity of *Aspergillus* GM test in parallel to blood culture and clinical and radiological features for diagnosis of probable *Aspergillus* infection

	Sensitivity	Specificity	PPV	NPV	Accuracy
Aspergillus galactomannan antigen test with blood culture	100%	74%	36%	100%	78%
Aspergillus galactomannan antigen test with Clinical and radiological features	80%	74%	31%	96%	75%

Table 4. Comparison of clinical features among the studied patients' groups

	Proven (n=5) No. (%)	Probable (n=10) No. (%)	Possible (n=25) No. (%)	P value
Age (mean ±SD, range)	54.20 ± 9.85	49.00 ± 9.41	53.28 ± 10.41	0.55
Gender				
Male	4 (80.0)	5 (50.0)	17 (68.0)	0.55
Female	1 (20.0)	5 (50.0)	8 (32.0)	
Underlying haematological diseases				
CLL	2(40.0)	2(20.0)	4 (16.0)	
AML	0 (0.0)	2 (20.0)	2 (8.0)	
NHL	2 (40.0)	5 (50.0)	16 (64.0)	0.754
ALL	1 (20.0)	1 (10.0)	2 (8.0)	
Relapsed HD	0 (0.0)	0 (0.0)	1 (4.0)	
Bacterial culture				
Positive	5 (100.0)	0 (0.0)	10 (40.0)	<0.001
Negative	0 (0.0)	10 (100.0)	15 (60.0)	
Body temperature				
High grade fever	5 (100.0)	10 (100.0)	25 (100.0)	------
Normal body temperature	0 (0.0)	0 (0.0)	0 (0.0)	
Neutropenia (< 500)				
Present	5 (100.0)	10 (100.0)	25 (100.0)	------
Absent	0 (0.0)	0 (0.0)	0 (0.0)	
Antibiotic administration				
Yes	5 (100.0)	10 (100.0)	25 (100.0)	------
No	0 (0.0)	0 (0.0)	0 (0.0)	
Radiological finding				
Yes	2 (40.0)	6 (60.0)	0 (0.0)	<0.001
No	3 (60.0)	4 (40.0)	25 (100.0)	

Bad prognosis are reported in patients infected with invasive aspergillosis ,our results showed that high GM indices in serum of patients with IA positively correlated with fatal outcome, as 50% of patients infected with IA died and; this is also reported with Penack et al. [17], Sheppard et al. [21] and Maertens et al. [22].

Among the three studied groups; there was no relation between category of invasive fungal

Table 5. Prognosis of hematological malignancies' patients and patients with Invasive aspergillosis

	Fate		Fisher's Exact test	P value
	Passed	**Died**		
Aspergillus galactomannan antigen test				
Negative	22 (84.6)	4 (15.4)	5.46	0.029
Positive	7 (50.0)	7 (50.0)		
Aspergillus culture				
Negative	28 (80.0)	7 (20.0)	7.90	0.015
Positive	1 (20.0)	4 (80.0)		

infection and their diagnosis, This was against results of Racil et al. [23] who reported that proven and probable fungal infection was more prevalent among leukemic patients and this difference can be related to difference in sample composition as most of our patients were diagnosed with lymphoma.

The incidence of bacterial culture positivity was more among cases of possible fungal infection (40%) and this explains the uncontrolled fever among this group of immune compromised patients.

In the diagnosis of invasive aspergillosis, the GM ELISA was positive before other microbiologic evidence of Aspergillosis was available (within 48 to 72 hours). While the average period for Aspergillus culture was 3 to 10 days.

The cost per patient of *Aspergillus* GM antigen test was cheaper (133 Egyptian pounds) in comparison with fungal blood culture (200 Egyptian pounds). Being a good negative, rapid and affordable test, we recommend *Aspergillus* GM antigen test to be done routinely for any patient suspected of having fungal infection.

5. CONCLUSION AND RECOMMENDA-TION

The authors recommend checking serum GM antigen assay as a screening test for hematologic malignancies. The results of GM antigen assays, if positive, can be used to support the diagnosis of probable fungal infection in patients who also meet the host factors and clinical criteria and should encourage the physician to start empiric antifungal therapy. Negative results of GM antigen assays in patients with persistent neutropenic fever without clinical or radiologic findings are more helpful in supporting the absence of IA and avoiding empiric anti-mold treatment. Further studies with

attention to the impact of antifungal therapy, rigorous assessment of false-positive test results, and assessment of the utility of the test under non-surveillance conditions are needed.

CONSENT

As per international standard or university standard, patient's written consent has been collected and preserved by the authors.

ETHICAL APPROVAL

As per international standard and university standard, written approval of Ethics committee has been collected and preserved by the authors.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Yeh TC, Liu HC, Wang LY, et al. Invasive fungal infection in children undergoing chemotherapy for cancer. Ann Trop Paediatr. 2007;27:141-7.
2. Ahmad A, Gupta P, Kumar A, et al. Evaluation of galactomannan for the diagnosis of invasive aspergillosis at different cutoff values in pediatric cancer patients. Life Science Informatics Publications RJLBPCS. 2017;3(3):125.
3. Riwes M, Wingard J. Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies. Expert Rev Hematol. 2012;5(6):661–669.
   DOI: 10.1586/ehm.12.53
4. Lamoth F. Galactomannan and 1,3-β-D-glucan testing for the diagnosis of invasive aspergillosis. J. Fungi. 2016;2:22.
   DOI: 10.3390/jof2030022

5. Jenks J, Hoenig M. Treatment of aspergillosis. J Fungi (Basel). 2018;4(3): 98.

6. Zhou W, Li H, Zhang Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol. 2017;55(7):2153–2161.

7. De Pauw B, Walsh TJ, Donnelly JP, et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008; 46(12):1813–1821. [PubMed: 18462102]

8. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4(6):349–357.

9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 2005;49(9):3640–3645. [PubMed: 16127033]

10. Milne LJR. Fungi. In: Mackie and McCartney, Practical Medical Microbiology, Collee J.G., Marmion B. P., Fraser A.G. And Simmons A. (Eds). 14th Edition. Churchill Livingstone, New York. 1996;1:695-717.

11. Murray PR, Baron EJ, Faller MA, et al. Manual of clinical microbiology. 8th Ed. ASM Press, Washington, DC; 2003.

12. Cheesbrough M. Microbiological tests in: District laboratory practice in tropical countries, Part II: Microbiology. Cambridge University press. Great Britain. 2000;1-266.

13. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 2010;50:1091–1100.

14. Boch T, Spiess B, Cornely OA, Vehreschild JJ, et al. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-b-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs inblood and bronchoalveolar lavage samples: results of a prospective multicentre study. Clinical Microbiology and Infection. 2016;22:862-868.

15. Zhang S, Wang S, Wan Z, et al. The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay. BioMed Research International. 2015;5. Article ID: 943691. Available:http://dx.doi.org/10.1155/2015/94 3691

16. Dos Santosa JS, Hermesa DM, Pasqualotto AC. Galactomannan use in clinical practice: Providing free testing is not the full answer. Braz J Infect Dis. 2018;22(1):37–40.

17. Penack O, Rempf P, Graf BI, et al. Aspergillus galactomannan testing in patients with long-term neutropenia: Implications for clinical management. Ann. Oncol. 2008;19:984-989.

18. Foy PC, van Burik JH, Weisdorf DJ. Galactomannan antigen enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2007;13:440-443.

19. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis. 2006;42(10):1417-27. Epub 2006 Apr 14.

20. Tănase AD, Coliţă A, Mărculescu A, et al. Using the galactomannan antigen assay in the diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Rom J Morphol Embryol. 2012;53(2):379–382.

21. Sheppard DC, Marr KA, Fredricks DN, et al. Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. Clin Microbiol Infect. 2006;12:376-380.

22. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood. 2001;97:1604–1610.

23. Racila Z, Weinbergerova B, Kocmanova I, et al. Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal Infection Database (FIND) analysis, 2005–2009. International Journal of Infectious Diseases. 2013;17:101–109.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle3.com/review-history/49967